Targeting the source.
Transforming the outcome.

miRNA-based therapies for neurological diseases.

Read more

Working towards a future where all patients with neurological diseases are effectively treated

We are committed to unlocking the full potential of miRNA therapy as a new frontier in the treatment of neurological diseases. With diligence and creativity, we advance promising therapies that harness the power of miRNA biology to effectively treat diseases such as Epilepsy and Parkinson’s.

We believe that real progress comes when diverse minds converge to challenge assumptions, reframe problems, and open entirely new ways forward. At every step, we engage closely with patients, caregivers, and the medical community to ensure we are working towards outcomes that are truly life changing.

Our Science
Our miRNA-targeting approach restores balance by guiding neural networks back to healthy function.
Read more
For Patients
‍Conventional medicine for neurological disease has limitations. By correcting the root causes of disease, our miRNA therapies remedy its diverse impacts for improved patient outcomes.
Read more

Latest development updates, scientific publications and industry perspectives

30.9.2026
Neumirna presents preclinical Parkinson's disease data at AD/PD
Data presented at AD/PD show that targeting miR-27b may influence several interconnected biological processes implicated in Parkinson's disease.
Read more
22.9.2026
Disa Tehler Joins Neumirna as Head of RNA Therapeutics
Neumirna Therapeutics is pleased to welcome Disa Tehler as Head of RNA Therapeutics, further strengthening the company’s expertise in RNA biology and oligonucleotide drug discovery.
Read more
29.4.2026
Dr. Ferenc Tracik Joins Neumirna as Chief Medical Officer
We are excited to announce the appointment of Dr. Ferenc Tracik as Neumirna’s Chief Medical Officer (CMO).
Read more
See all news

Investors

Work with us

Interested in joining Neumirna? Explore current career opportunities or contact us to learn how you can contribute to our mission.

Learn more

Stay in the Loop

Sign up to receive updates on our most important milestones, including scientific progress, company news, and press announcements.

Thank you! Your submission has been received.
Oops! Something went wrong while submitting the form.